Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

JetBlue Airways Corp JBLU

JetBlue Airways Corporation is a travel company. It provides air transportation services across the United States, the Caribbean, Latin America, Canada and the United Kingdom. Its segments include Domestic, and Caribbean & Latin America. It operates five types of aircraft: Airbus A220, Airbus A320, Airbus A321, Airbus A321neo, and Embraer E190. Airbus A220 aircraft have 140 seats in a single cabin layout. It has eight of Airbus A220 aircraft in its fleet. Airbus A320 aircraft in the classic configuration have 150 seats and those A320 aircraft, which have gone through its cabin restyling program have 162 seats. It has 113 restyled Airbus A320 aircraft in service. Airbus A321 aircraft in a single cabin layout have 200 seats and those with its Mint offering have 159 seats. Airbus A321neo aircraft have 200 seats and those with its Mint offering have 160 seats. The long-range version of its A321neo aircraft with Mint offering have 138 seats while its Embraer E190 aircraft have 100 seats.


NDAQ:JBLU - Post by User

User Avatar Image
(0)
•••
  • KarenCarX
Post by KarenCaron Jun 03, 2022 4:01am
96 Views
Post# 34728669

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>